Belpointe Asset Management LLC Esperion Therapeutics, Inc. Transaction History
Belpointe Asset Management LLC
- $1.69 Billion
- Q1 2025
A detailed history of Belpointe Asset Management LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Belpointe Asset Management LLC holds 38,000 shares of ESPR stock, worth $32,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,000
Previous 47,000
19.15%
Holding current value
$32,300
Previous $103,000
47.57%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ESPR
# of Institutions
200Shares Held
119MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$11.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.5MShares$9.76 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT10.9MShares$9.29 Million0.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$8.24 Million0.32% of portfolio
-
Two Seas Capital LP Rye, NY6.93MShares$5.89 Million0.36% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $56.6M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...